PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)
Primary Target and PDB code of Protein-Drug complex
ANTIINFECTIVE ANTIVIRAL ANTIRETROVIRAL NUCLEOTIDE ANALOG HIV-1 REVERSE TRANSCRIPTASE INHIBITOR AND HBV REVERSE TRANSCRIPTASE INHIBITOR CHRONIC HEPATITIS B IN ADULTS
-
Cmax 0.578 MICROMOLAR (300 MILLIGRAM)
F 25 PERCENT
VD 84.5 LITER (65 KILOGRAM)
PPB 7 PERCENT
Cl 3.4 LITER / HOUR (EQN)
HT 17 HOUR
HIV REVERSE TRANSCRIPTASE
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REVERSE TRANSCRIPTASE INHIBITOR CHEMBL247 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REVERSE TRANSCRIPTASE Q72547 REVERSE TRANSCRIPTASE/RNASEH HUMAN IMMUNODEFICIENCY VIRUS 1 ENZYME HYDROLASE
PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)
Primary Target and PDB code of Protein-Drug complex
ANTIINFECTIVES TREATMENT OF HIV-1 INFECTION CONVERTED IN VIVO TO TENOFOVIR
ORAL
Cmax 0.33 MICROMOLAR
Tmax 1 HOUR
PPB 80 PERCENT
HT 0.51 HOUR
SOLUBILITY 4.7 MILLIGRAM / MILLILITER
HIV REVERSE TRANSCRIPTASE
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REVERSE TRANSCRIPTASE INHIBITOR CHEMBL247 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REVERSE TRANSCRIPTASE Q72547 REVERSE TRANSCRIPTASE/RNASEH HUMAN IMMUNODEFICIENCY VIRUS 1 ENZYME HYDROLASE